Dual role for microbial short-chain fatty acids in modifying SIV disease trajectory following anti-α4β7 antibody administration

Samuel D. Johnson,Nageswara Pilli,Jianshi Yu,Lindsey A. Knight,Maureen A. Kane,Siddappa N. Byrareddy
DOI: https://doi.org/10.1080/07853890.2024.2315224
IF: 5.348
2024-02-16
Annals of Medicine
Abstract:Background Human Immunodeficiency Virus (HIV)/Simian Immunodeficiency Virus (SIV) infection is associated with significant gut damage, similar to that observed in patients with inflammatory bowel disease (IBD). This pathology includes loss of epithelial integrity, microbial translocation, dysbiosis, and resultant chronic immune activation. Additionally, the levels of all- trans -retinoic acid (atRA) are dramatically attenuated. Data on the therapeutic use of anti-α4β7 antibodies has shown promise in patients with ulcerative colitis and Crohn's disease. Recent evidence has suggested that the microbiome and short-chain fatty acid (SCFA) metabolites it generates may be critical for anti-α4β7 efficacy and maintaining intestinal homeostasis.
medicine, general & internal
What problem does this paper attempt to address?